Literature DB >> 19084003

The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning.

John C Dreixler1, Jonathan W Hemmert, Shanti K Shenoy, Yang Shen, H Thomas Lee, Afzhal R Shaikh, Daniel M Rosenbaum, Steven Roth.   

Abstract

Potent endogenous protection from ischemia can be induced in the retina by ischemic preconditioning (IPC). Protein kinase B/Akt is a cellular survival factor. We hypothesized that Akt was integral to IPC based upon differential effects of Akt subtypes. Rats were subjected to retinal ischemia after IPC or IPC-mimicking by the opening of mitochondrial KATP (mKATP) channels. The effects of blocking Akt using wortmannin, API-2, or small interfering RNA (siRNA) were examined. Electroretinography assessed functional recovery after ischemia, and TUNEL examined retinal ganglion cell apoptosis. We studied the relationship between Akt activation and known initiators of IPC, including adenosine receptor stimulation and the opening of mKATP channels. The PI-3 kinase inhibitor wortmannin 1 or 4 mg/kg (i.p.), the specific Akt inhibitor API-2, 5-500 microM in the vitreous, or intravitreal siRNA directed against Akt2 or -3, but not Akt1, significantly attenuated the neuroprotective effect of IPC. Interfering RNA against any of the three Akt subtypes significantly but time-dependently attenuated mKATP channel opening to mimic IPC. Adenosine A1 receptor blockade (DPCPX), A2a blockade (CSC), or the mKATP channel blocker 5-hydroxydecanoic acid significantly attenuated Akt activation after IPC. Interfering RNA directed against Akt subtypes prevented the ameliorative effect of IPC on post-ischemic apoptosis. All three Akt subtypes are involved in functional retinal neuroprotection by IPC or IPC-mimicking. Akt is downstream of adenosine A1 and A2a receptors and mKATP channel opening. The results indicate the presence in the retina of robust and redundant endogenous neuroprotection based upon subtypes of Akt.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084003      PMCID: PMC2709455          DOI: 10.1016/j.exer.2008.11.013

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  52 in total

1.  Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury.

Authors:  Toru Nakazawa; Masahiko Shimura; Hiroshi Tomita; Hiroshi Akiyama; Yuki Yoshioka; Hideyo Kudou; Makoto Tamai
Journal:  Curr Eye Res       Date:  2003-01       Impact factor: 2.424

Review 2.  Akt is a molecular target for signal transduction therapy in brain ischemic insult.

Authors:  Kohji Fukunaga; Takayuki Kawano
Journal:  J Pharmacol Sci       Date:  2003-08       Impact factor: 3.337

3.  ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases.

Authors:  Thomas Krieg; Qining Qin; Elizabeth C McIntosh; Michael V Cohen; James M Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08-22       Impact factor: 4.733

4.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

5.  Characterization of insulin signaling in rat retina in vivo and ex vivo.

Authors:  Chad E N Reiter; Lakshman Sandirasegarane; Ellen B Wolpert; Marianne Klinger; Ian A Simpson; Alistair J Barber; David A Antonetti; Mark Kester; Thomas W Gardner
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-06-10       Impact factor: 4.310

6.  Ischemic preconditioning attenuates apoptotic cell death in the rat retina.

Authors:  Cheng Zhang; Daniel M Rosenbaum; Afzhal R Shaikh; Qing Li; Pearl S Rosenbaum; Daniel J Pelham; Steven Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-09       Impact factor: 4.799

7.  Neuroprotective role of a proline-rich Akt substrate in apoptotic neuronal cell death after stroke: relationships with nerve growth factor.

Authors:  Atsushi Saito; Purnima Narasimhan; Takeshi Hayashi; Shuzo Okuno; Michel Ferrand-Drake; Pak H Chan
Journal:  J Neurosci       Date:  2004-02-18       Impact factor: 6.167

8.  Mitogen-activated protein kinases and retinal ischemia.

Authors:  Steven Roth; Afzhal R Shaikh; Meghann M Hennelly; Qing Li; Vytas Bindokas; Christine E Graham
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-12       Impact factor: 4.799

9.  Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Authors:  Lin Yang; Han C Dan; Mei Sun; Qiyuan Liu; Xia-meng Sun; Richard I Feldman; Andrew D Hamilton; Mark Polokoff; Santo V Nicosia; Meenhard Herlyn; Said M Sebti; Jin Q Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

10.  Up-regulation of endothelial nitric oxide synthase via phosphatidylinositol 3-kinase pathway contributes to ischemic tolerance in the CA1 subfield of gerbil hippocampus.

Authors:  Akihito Hashiguchi; Shigetoshi Yano; Motohiro Morioka; Junichiro Hamada; Yukitaka Ushio; Yusuke Takeuchi; Kohji Fukunaga
Journal:  J Cereb Blood Flow Metab       Date:  2004-03       Impact factor: 6.200

View more
  18 in total

1.  Mitogen-activated protein kinase phosphatase-1 (MKP-1) in retinal ischemic preconditioning.

Authors:  John C Dreixler; Anthony Bratton; Eugenie Du; Afzhal R Shaikh; Brian Savoie; Michael Alexander; Marcus M Marcet; Steven Roth
Journal:  Exp Eye Res       Date:  2010-11-20       Impact factor: 3.467

2.  Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Authors:  Jeffrey M Gidday
Journal:  Cond Med       Date:  2018-02-15

3.  Caffeine exposure ameliorates acute ischemic cell death in avian developing retina.

Authors:  D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza
Journal:  Purinergic Signal       Date:  2020-02-20       Impact factor: 3.765

4.  Post-ischemic conditioning in the rat retina is dependent upon ischemia duration and is not additive with ischemic pre-conditioning.

Authors:  John C Dreixler; Afzhal R Shaikh; Michael Alexander; Brian Savoie; Steven Roth
Journal:  Exp Eye Res       Date:  2010-06-23       Impact factor: 3.467

5.  Protein kinase B (Akt) and mitogen-activated protein kinase p38α in retinal ischemic post-conditioning.

Authors:  John C Dreixler; Ajay Sampat; Afzhal R Shaikh; Michael Alexander; Marcus M Marcet; Steven Roth
Journal:  J Mol Neurosci       Date:  2011-05-15       Impact factor: 3.444

6.  Bone-marrow mesenchymal stem-cell administration significantly improves outcome after retinal ischemia in rats.

Authors:  Biji Mathew; Jacqueline N Poston; John C Dreixler; Leianne Torres; Jasmine Lopez; Ruth Zelkha; Irina Balyasnikova; Maciej S Lesniak; Steven Roth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-05-18       Impact factor: 3.117

Review 7.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

8.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

9.  Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Jinling Hou; Kenneth Maiese
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

10.  Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning.

Authors:  John C Dreixler; Frank C Barone; Afzhal R Shaikh; Eugenie Du; Steven Roth
Journal:  Exp Eye Res       Date:  2009-07-24       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.